Two Sigma Securities LLC increased its stake in Celgene Corporation (NASDAQ:CELG) by 92.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,719 shares of the biopharmaceutical company’s stock after buying an additional 3,225 shares during the period. Two Sigma Securities LLC’s holdings in Celgene Corporation were worth $836,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Motco boosted its stake in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Celgene Corporation during the first quarter worth about $118,000. Carroll Financial Associates Inc. boosted its stake in shares of Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. boosted its stake in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the period. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares during the period. Institutional investors own 78.41% of the company’s stock.

Celgene Corporation (NASDAQ CELG) traded up 0.37% on Friday, reaching $130.85. The company’s stock had a trading volume of 1,019,500 shares. The stock has a 50 day moving average price of $134.23 and a 200-day moving average price of $124.17. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a market capitalization of $102.37 billion, a price-to-earnings ratio of 40.52 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period last year, the firm earned $1.44 earnings per share. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. Equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Two Sigma Securities LLC Buys 3,225 Shares of Celgene Corporation (CELG)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/two-sigma-securities-llc-buys-3225-shares-of-celgene-corporation-celg.html.

A number of analysts have weighed in on the company. Jefferies Group LLC set a $154.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Saturday, May 13th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday. Vetr raised Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a research report on Thursday. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a research report on Friday, July 14th. Finally, Argus raised Celgene Corporation from a “hold” rating to a “buy” rating and increased their price objective for the stock from $96.93 to $160.00 in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. Celgene Corporation presently has an average rating of “Buy” and a consensus price target of $147.00.

In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 235,255 shares of company stock worth $31,377,042. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.